Elixir Medical's DynamX BTK System Receives FDA Breakthrough Device Designation for Chronic Limb-Threatening Ischemia
核心洞察
Elixir Medical (搜索)'s DynamX BTK System (搜索) receives FDA Breakthrough Device Designation for treating below-the-knee arterial disease in chronic limb-threatening ischemia (搜索) (CLTI) patients.
The DynamX Bioadaptor platform aims to restore vessel function by providing dynamic support during healing and maintaining an open lumen in affected vessels.
The breakthrough designation expedites the review process, acknowledging the technology's potential to address unmet needs in treating severe peripheral arterial disease (搜索).
Elixir Medical (搜索) has announced that its DynamX BTK System (搜索) has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). This designation is for the treatment of narrowed or blocked vessels below-the-knee (BTK) in patients suffering from chronic limb-threatening ischemia (搜索) (CLTI), the most severe form of peripheral arterial disease (搜索) (PAD). The DynamX BTK System expands the application of Elixir's bioadaptor platform beyond coronary artery disease.
The DynamX Bioadaptor is designed to support the vessel during the healing phase, after which it unlocks to restore vessel function and maintain an open lumen. This mechanism aims to address the challenges of existing BTK therapies, such as maintaining long-term lumen gain.
The Burden of Peripheral Arterial Disease
PAD affects over 200 million people globally. CLTI, the advanced stage of PAD, carries a high risk of mortality, with one-year mortality estimates exceeding 20% in observational studies. Without revascularization, a significant number of CLTI patients require major amputation.
How DynamX Bioadaptor Works
The DynamX Bioadaptor has demonstrated high acute lumen gain in coronary vessels and maintained this gain over time. It also restores vessel motion and function, including positive adaptive remodeling, vessel pulsatility, improved vessel dynamic compliance, and increased blood flow volume.
"The Bioadaptor platform was developed to transform treatment of coronary and peripheral artery disease," said Motasim Sirhan, CEO at Elixir Medical (搜索). "We appreciate the FDA recognition of our innovation for treating the CLTI population with BTK disease and its potential impact on the patients suffering from vascular disease."
FDA Breakthrough Device Designation
The FDA Breakthrough Device Designation is granted to novel technologies that address unmet medical needs, accelerating their review process. Devices receiving this designation must meet rigorous standards for safety and effectiveness before being authorized for marketing.
About DynamX Bioadaptor Technology
The DynamX Bioadaptor is designed to unlock, uncage, and restore normal vessel motion and function after percutaneous coronary intervention (PCI) or BTK intervention. It maintains dynamic support of the diseased vessel after uncaging, aiming to set a new standard of care for vascular intervention.
The DynamX BTK System (搜索) is currently not available for sale in the U.S.